Drug Trial Radar · NCT01690702
Study of Nab-Paclitaxel in High Risk Early Breast Cancer
Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,886
Actual
Start
Sep 2012
Primary completion
Sep 30, 2018
Study completion Jul 20, 2020
Sponsor
- Lead sponsor
- GBG Forschungs GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Celgene; Amgen
- First posted
- Sep 24, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
two-armed trial to compare E-nP-C against tailored dtEC-dtD in patients with high risk early breast cancer
Conditions
- Breast Cancer
Interventions
EpirubicinDrug
nab-PaclitaxelDrug
CyclophosphamideDrug
DocetaxelDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- invasive disease-free survival (IDFS)Time frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Klinikum Frankfurt Höchst
Frankfurt am Main, Hesse, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.